GS
ALNY icon

GTS Securities’s Alnylam Pharmaceuticals ALNY Stock Holding History

GTS Securities’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-27,200
Closed -$7.48M – 1336
2024
Q3 		$7.48M Sell
27,200
-26,700
-50% -$6.95M 0.02% 646
2024
Q2 		$13.1M Buy
53,900
+6,600
+14% +$1.04M 0.03% 394
2024
Q1 		$7.07M Buy
47,300
+5,600
+13% +$934K 0.01% 670
2023
Q4 		$7.98M Buy
41,700
+300
+0.7% +$51.1K 0.01% 725
2023
Q3 		$7.33M Buy
+41,400
New +$7.9M 0.01% 735

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GTS Securities's ALNY Position: Q1 2026 in Review

GTS Securities increased its Alnylam Pharmaceuticals (ALNY) stake by 100% in Q1 2026, buying an estimated $179K and bringing the position to 1,052 shares worth $348K. The position accounts for 0.01% of the portfolio, ranked #1007.

GTS Securities first reported a position in ALNY in Q4 2023 and has held it in 7 quarters since. The position peaked at $2.26M in Q3 2024. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • GTS Securities held 1,052 shares of Alnylam Pharmaceuticals worth $348K as of Q1 2026.
  • GTS Securities bought 527 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $179K.
  • Alnylam Pharmaceuticals made up 0.01% of GTS Securities's portfolio in Q1 2026, its #1007 holding.
  • GTS Securities first reported a position in Alnylam Pharmaceuticals in Q4 2023 and has held it in 7 quarters since.
  • GTS Securities's Alnylam Pharmaceuticals position peaked at $2.26M in Q3 2024.
  • 787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on GTS Securities's 13F filing for Q1 2026, filed 15 May 2026.